Qwell Pharmaceuticals Inc is categorized under Biological Products Manufacturers in Seattle, WA and active since 2008.
Qwell Pharmaceuticals Inc was established in 2008, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Biological Products Manufacturers business, which does work in the B2B market, and is classified as a Biological Products Manufacturers, under code number 325414 by the NAICS.
If you are seeking more information, feel free to contact Steven Gillis at the company’s single location by writing to 1000 2nd Avenue # 3700, Seattle, Washington WA 98104 or by phoning (206) 674-3027. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Qwell Pharmaceuticals Inc |
| Contact Person: | Steven Gillis |
| Address: | 1000 2nd Avenue # 3700, Seattle, Washington 98104 |
| Phone Number: | (206) 674-3027 |
| Annual Revenue (USD): | $50.000 to $99.999 |
| Founded: | 2008 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Biological Products Manufacturers |
| SIC Code: | 2836 |
| NAICS Code: | 325414 |
| Share This Business: |
Qwell Pharmaceuticals Inc was started in 2008 to provide professional Biological Products Manufacturers under the SIC code 2836 and NAICS code 325414. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact Steven Gillis for inquiries that concern Qwell Pharmaceuticals Inc by calling the company number (206) 674-3027, as your correspondence is most welcome. Additionally, the physical location of the single location of Qwell Pharmaceuticals Inc can be found at the coordinates 47.605585,-122.33528 as well as the street address 1000 2nd Avenue # 3700 in Seattle, Washington 98104.
For its online presence, you may visit Qwell Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.